Abstract

BackgroundPatients with advanced cancer for whom standard systemic treatment is no longer available may be offered participation in early phase clinical trials. In the decision making process, both medical-technical information and patient values and preferences are important. Since patients report decisional conflict after deciding on participation in these trials, improving the decision making process is essential. We aim to develop and evaluate an Online Value Clarification Tool (OnVaCT) to assist patients in clarifying their values around this end-of-life decision. This improved sharing of values is hypothesized to support medical oncologists in tailoring their information to individual patients’ needs and, consequently, to support patients in taking decisions in line with their values and reduce decisional conflict.MethodsIn the first part, patients’ values and preferences and medical oncologists’ views hereupon will be explored in interviews and focus groups to build a first prototype OnVaCT using digital communication (serious gaming). Next, we will test feasibility during think aloud sessions, to deliver a ready-to-implement OnVaCT. In the second part, the OnVaCT, with accompanied training module, will be evaluated in a pre-test (12–18 months before implementation) post-test (12–18 months after implementation) study in three major Dutch cancer centres. We will include 276 patients (> 18 years) with advanced cancer for whom standard systemic therapy is no longer available, and who are referred for participation in early phase clinical trials. The first consultation will be recorded to analyse patient-physician communication regarding the discussion of patients’ values and the decision making process. Three weeks afterwards, decisional conflict will be measured.DiscussionThis project aims to support the discussion of patient values when considering participation in early phase clinical trials. By including patients before their first appointment with the medical oncologist and recording that consultation, we are able to link decisional conflict to the decision making process, e.g. the communication during consultation. The study faces challenges such as timely including patients within the short period between referral and first consultation. Furthermore, with new treatments being developed rapidly, molecular stratification may affect the patient populations included in the pre-test and post-test periods.Trial registrationNetherlands Trial Registry number: NTR7551 (prospective; July 17, 2018).

Highlights

  • Patients with advanced cancer for whom standard systemic treatment is no longer available may be offered participation in early phase clinical trials

  • Despite improved molecular stratification for experimental therapy and improved anti-cancer activity in these clinical trials [1], the majority of patients do not benefit from participation

  • Overall aim The overall aim of the project is to study whether a preparatory online value clarification tool decreases decisional conflict in patients who are considering participation in early phase clinical trials, by improving patient-physician communication with respect to the discussion of patients’ preferences and the decision making process

Read more

Summary

Introduction

Patients with advanced cancer for whom standard systemic treatment is no longer available may be offered participation in early phase clinical trials. We aim to develop and evaluate an Online Value Clarification Tool (OnVaCT) to assist patients in clarifying their values around this end-of-life decision This improved sharing of values is hypothesized to support medical oncologists in tailoring their information to individual patients’ needs and, to support patients in taking decisions in line with their values and reduce decisional conflict. Some are still in a relatively good condition and may live for several months or longer Those patients may be asked and/or considered to participate in early phase clinical trials. These trials are a major prerequisite for the further development of efficacious anti-cancer therapies. Trial participation may interfere with adequate end-of-life decision making

Objectives
Methods
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call